OVID Ovid Therapeutics Inc.

CIK 0001636651 50 ready 8-Ks latest July 8, 2026, 7:03 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing July 8, 2026, 7:03 AM ET

Top materiality 0.85

Event mix other_material ×21 · earnings ×14 · leadership ×7

Sentiment 16 pos · 7 neg · 27 neu

Latest earnings reported 2024-Q3

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for OVID

Highest-materiality recent filing

Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing

October 3, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 5.03 item 8.01 item 9.01 ◈ Equity Issuances ×3◈ Governance Changes

OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.
No ophthalmic changes observed; plan Phase 2a in drug-resistant focal onset seizures Q2 2026.

Read filing →

July 8, 2026, 7:03 AM ET leadership materiality 0.60 neutral item 5.02

Ovid Therapeutics appoints Charles Carter as CFO, replacing Jeffrey Rona

CFO Jeffrey Rona departed July 6, 2026; no disagreement with company on accounting or financial reporting.
June 11, 2026, 9:03 AM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Ovid Therapeutics stockholders elect Jeremy Levin as director, approve advisory say-on-pay and ratify KPMG as auditor

Jeremy M. Levin elected as director with 87,219,707 for, 8,528,008 withheld.
June 3, 2026, 7:03 AM ET leadership materiality 0.30 positive item 5.02 ◈ executive_change

Ovid Therapeutics appoints Dr. Anna Greka to Board of Directors

Board increased to seven directors, effective June 15, 2026, with appointment of Anna Greka, M.D., Ph.D. as Class III director.
May 12, 2026, 7:04 AM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Ovid Q1 net loss $17M; raises $60M PIPE; dosed first OV4071 Phase 1; OV329 Phase 2 planned

Q1 2026 net loss of $17.0M ($0.12/share) vs $10.2M loss ($0.14) in Q1 2025.
April 20, 2026, 7:59 PM ET other material materiality 0.70 neutral item 8.01

Ovid Therapeutics receives $53.9M from exercise of Series A warrants; issues 33.6M common shares

Series A warrants from Oct 2025 private placement expired on April 17, 2026; 38,481,325 underlying shares.
March 18, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01 item 2.02 item 3.02 item 9.01 ◈ Equity Issuances ×2◈ Material Agreements

Ovid Therapeutics raises $60M PIPE, reports positive OV329 data, expands indications, and clears OV4071 for Phase 1

$60M PIPE: 19.15M shares at $2.01 and pre-funded warrants for 10.7M shares; closing expected March 19, 2026.
December 18, 2025, 6:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

Ovid reports Phase 1 safety and PK for OV350; oral KCC2 activator OV4071 on track for Q1 2026 filing

OV350 IV showed good safety; no treatment-related SAEs or lab findings in 16 healthy participants.
December 11, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07

Ovid Therapeutics stockholders approve 3 proposals at special meeting including authorized share increase to 315M

Approved amendment to increase authorized common shares from 125M to 315M: 34.2M for, 1.5M against, 2.4M abstain.
November 12, 2025, 6:59 PM ET leadership materiality 0.70 positive item 2.02 item 5.02 item 9.01

Ovid Therapeutics announces CEO succession, Q3 2025 loss, and pipeline progress

Meg Alexander appointed CEO effective Jan 1, 2026; Jeremy Levin to become Executive Chairman.
October 3, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01 item 3.02 item 5.03 item 8.01 item 9.01 ◈ Equity Issuances ×3◈ Governance Changes

Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing

OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.
September 16, 2025, 7:59 PM ET regulatory materiality 0.50 positive item 8.01

Ovid Therapeutics regains compliance with Nasdaq minimum bid price rule

Received formal notice from Nasdaq on Sept 11, 2025, confirming compliance with Listing Rule 5550(a)(2).
August 13, 2025, 7:59 PM ET other material materiality 0.65 negative item 2.02 item 3.01 item 9.01 ◈ Listing & Compliance Notices

Ovid Therapeutics Q2 net loss $4.7M, cash $38.3M; receives Nasdaq extension to Feb 2026

Net loss of $4.7M ($0.06 EPS) vs net income of $8.5M ($0.12 EPS) in Q2 2024.
July 10, 2025, 7:59 PM ET other material materiality 0.30 neutral item 5.07

Ovid Therapeutics shareholders approve reverse stock split authorization at annual meeting

Elected directors Kevin Fitzgerald and Bart Friedman to three-year terms with >35M votes for each.
June 25, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01 item 9.01

Ovid sells future ganaxolone royalties to Immedica for $7.0M cash

Immedica pays $7.0M to acquire 100% of Ovid's royalty rights on ganaxolone sales outside China.
May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Ovid Therapeutics Q1 net loss $10.2M; OV329 data on track for Q3 2025

Cash and equivalents $43.0M at March 31, 2025; expected to fund operations into 2H 2026.
May 2, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.08

Ovid Therapeutics sets 2025 Annual Meeting for July 9; shareholder proposal deadline May 12

Annual Meeting scheduled for July 9, 2025; record date for voting is May 19, 2025.
March 11, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.02 item 9.01

Ovid Therapeutics Q4/FY2024 net loss $26.4M; cash into H2 2026; OV329 data Q3 2025

Net loss $26.4M ($0.37/diluted) for FY2024 vs $52.3M in 2023; royalty revenue $566K.
March 5, 2025, 6:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Ovid Therapeutics appoints Stelios Papadopoulos to Board of Directors

Board expanded from five to six directors; Papadopoulos appointed Class I director, term through 2027 annual meeting.
February 13, 2025, 6:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices ×2

Ovid Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

Received Nasdaq notice on Feb 10, 2025, that average closing bid price was below $1.00 for 31 consecutive trading days.
November 12, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Ovid Q3 net loss $14.0M ($0.20/share); cash $62.7M; pauses CCM Phase 2, advances OV329/OV350

Net loss of $14.0M ($0.20 per share) vs $11.3M in Q3 2023; royalty revenue $173K.
September 11, 2024, 7:59 PM ET leadership materiality 0.70 positive item 5.02 item 9.01 ◈ executive_change

Ovid Therapeutics appoints Meg Alexander as President and COO effective Sept 9

Annual base salary of $500,000; target bonus of 45% of base salary.
August 13, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Ovid Therapeutics cuts workforce 43%, suspends OV329 IV, reports Q2 net income of $8.5M on $77M cash

Reduced headcount by 17 employees (43%) to prioritize core programs; expects $3.4M cash restructuring costs through mid-2025.
August 2, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change

Ovid Therapeutics enters consulting agreement with departing General Counsel Thomas Perone

Thomas Perone departed as General Counsel, CCO and Corporate Secretary effective July 11, 2024, as part of a workforce reduction.
July 1, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01 item 9.01

Ovid/Graviton announce positive Phase 1 data for OV888/GV101 CCM therapy; Phase 2 expected H2 2024

Phase 1 met primary safety/tolerability objectives: no serious adverse events at any dose.
June 28, 2024, 7:59 PM ET other material materiality 0.75 negative item 2.05 item 5.02 item 7.01 ◈ executive_change ×2◈ Restructurings & Charges

Ovid Therapeutics cuts workforce by 43%, two executives depart

Workforce reduced by 17 employees (~43% of headcount); one-time severance charge of ~$4.0M; substantially complete by Q3 2024.
June 17, 2024, 7:59 PM ET other material materiality 0.75 negative item 7.01 item 9.01

Ovid reports Takeda's Ph3 soticlestat misses primary endpoints; pipeline and cash runway update

Takeda's Phase 3 SKYLINE in Dravet syndrome narrowly missed primary endpoint (p=0.06) but showed significant secondary endpoints (p≤0.008).
June 7, 2024, 7:59 PM ET other materiality 0.15 neutral item 5.07

Ovid Therapeutics stockholders elect directors, approve executive compensation, ratify KPMG

Proposal 1: Barbara Duncan and Robert Michael Poole elected to board; For votes 36.7M and 40.2M respectively.
May 14, 2024, 7:59 PM ET other material materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ovid Therapeutics reports Q1 2024 net loss of $11.7M; cash $90.3M; Takeda Phase 3 soticlestat data expected by Sep 2024

Net loss $11.7M ($0.17/share) vs $13.4M ($0.19) in Q1 2023; revenue $148K.
March 8, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ovid Therapeutics reports Q4 2023 financial results and pipeline updates; soticlestat Phase 3 enrollment complete

Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet syndromes completed enrollment; Takeda expects topline data by September 2024.
December 6, 2023, 6:59 PM ET other material materiality 0.35 neutral item 8.01

Ovid Therapeutics CEO gifts 1.15M shares to family trusts for estate planning

CEO Jeremy Levin gifted 1,146,500 shares of Ovid common stock to family trusts for his two daughters.
November 3, 2023, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01 ◈ Earnings Releases

Ovid Therapeutics Q3 net loss $11.3M; secures $30M from Ligand for soticlestat royalty interest

Received $30M from Ligand for 13% interest in soticlestat future royalties/milestones; cash runway extended into 2026.
October 18, 2023, 7:59 PM ET other material materiality 0.70 positive item 1.01 item 7.01 item 8.01 item 9.01 ◈ Material Agreements

Ovid sells 13% of soticlestat royalties & milestones to Ligand for $30M; cash runway into 2026

Ligand pays Ovid $30M (non-dilutive) for 13% of soticlestat regulatory/commercial milestones and tiered royalties (low double-digits to 20%).
October 2, 2023, 7:59 PM ET other materiality 0.20 neutral item 8.01 item 9.01

Ovid Therapeutics posts R&D Day corporate presentation; no financial or clinical updates

Presentation posted Oct 2, 2023, on Ovid investor relations website.
August 4, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ovid Therapeutics Q2 net loss $12.4M; OV329 SAD complete; Graviton ROCK2 collaboration

Cash and securities $96.5M as of June 30, 2023; net loss $0.18 per share vs $0.21 year ago.
June 9, 2023, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×4

Ovid Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor

Karen Bernstein re-elected with 39.7M for, 5.1M withheld; Jeremy Levin re-elected with 44.5M for, 0.4M withheld (16.5M broker non-votes).
May 5, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ovid Q1 net loss $13.4M; cash $117.7M; adds ROCK2 program via Graviton

Net loss $13.4M ($0.19 loss per share) vs $16.1M ($0.23) in Q1 2022; operating expenses $15.0M.
May 1, 2023, 7:59 PM ET M&A materiality 0.75 positive item 8.01 item 9.01

Ovid Therapeutics enters ROCK2 inhibitor collaboration with Graviton; invests $10M for exclusive CNS rights

Ovid pays $10M upfront in Graviton Series A preferred stock for exclusive license to GV101 and other ROCK2 inhibitors.
April 27, 2023, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Soticlestat long-term OLE data shows sustained seizure reduction in Dravet and LGS

ENDYMION 1 interim analysis: soticlestat generally safe and well tolerated over ~2 years; 78% tolerated 300 mg BID.
March 13, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ovid Therapeutics reports FY2022 net loss $54.2M; cash $129M; pipeline advancing

Net loss for FY2022 $54.2M ($0.77 per share) vs net income $122.8M ($1.78) in 2021, driven by prior Takeda milestone.
March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

Ovid Therapeutics confirms no exposure to Silicon Valley Bank

Company holds no deposits or securities at Silicon Valley Bank.
November 8, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Ovid Therapeutics Q3 2022 net loss $12.0M; $137.9M cash; OV329 Phase 1 to start Q4

Net loss of $12.0M ($0.17 per share) vs $11.4M loss in Q3 2021; R&D expense $5.2M.
August 9, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Ovid Therapeutics Q2 2022 net loss $14.6M; cash $152.4M; OV329 IND on track for H2 2022

Net loss $14.6M ($0.21 per share) vs $15.8M loss ($0.23) in Q2 2021.
June 10, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Ovid Therapeutics annual meeting elects two directors, ratifies KPMG

Annual meeting held June 9, 2022; 58.53% quorum (41,220,715 of 70,417,345 shares).
May 11, 2022, 7:59 PM ET other material materiality 0.75 negative item 8.01 item 9.01

Takeda notifies Ovid of soticlestat Phase 3 delays; primary completion March 2024

Takeda notified Ovid that two pivotal Phase 3 soticlestat trials (Dravet & Lennox-Gastaut) are likely delayed due to Ukraine/Russia and China COVID lockdowns.
May 10, 2022, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

Ovid reports Q1 net loss $16.1M, revenue $1.4M; OV329 IND on track for Q4 2022

Net loss $16.1M ($0.23/sh) vs net income $176M in Q1 2021 on one-time Takeda payment.
March 15, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Ovid Therapeutics reduces workforce 20%, extends cash runway beyond 2024; OV329 on track for 2022 clinical entry

Workforce reduced by ~20% to extend cash runway beyond 2024 as part of organizational restructuring.
January 3, 2022, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 3.02 item 7.01 item 9.01

Ovid licenses KCC2 activator library from AstraZeneca; $5M cash + $7.5M stock upfront

Exclusive worldwide license for early-stage small molecules targeting KCC2, including lead OV350.
November 10, 2021, 6:59 PM ET earnings materiality 0.50 neutral item 2.02 item 7.01 item 9.01

Ovid Therapeutics reports Q3 2021 net loss of $11.4M, cash $201.8M, and business development strategy

Cash and equivalents $201.8M as of Sept 30, 2021; net loss $11.4M ($0.17 per share) vs $16.4M ($0.28) in Q3 2020.
October 7, 2021, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Ovid Therapeutics appoints Dr. Kevin Fitzgerald as director, grants stock options

Appointed Dr. Kevin Fitzgerald, Ph.D. to Board as Class II director effective Oct 6, 2021.
August 18, 2021, 7:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Ovid posts August 2021 corporate overview; no specific financial or operational updates provided in filing

Company posted corporate presentation to website but full content not included in filing text.

Executive changes

Appointed

Anna Greka

Class III director

OVID · Ovid Therapeutics Inc.

Effective: 2026-06-15
Filed: June 3, 2026, 7:03 AM ET

On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the Company, with her term expiring at the Company’s 2029 annual meeting of stockholders.

Appointed

Stelios Papadopoulos

Class I director

OVID · Ovid Therapeutics Inc.

Effective: 2025-03-01
Filed: March 5, 2025, 6:59 PM ET

On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company

Appointed

Margaret "Meg" Alexander

President and Chief Operating Officer

OVID · Ovid Therapeutics Inc.

Effective: 2024-09-09
Filed: September 11, 2024, 7:59 PM ET

On September 8, 2024, the Board of Directors of Ovid Therapeutics Inc. (the “Company”) appointed Margaret “Meg” Alexander, the Company’s Chief Strategy Officer, to President and Chief Operating Officer (“COO”) of the Company, effective September 9, 2024.

Departed

Thomas Perone

General Counsel, Chief Compliance Officer and Corporate Secretary

OVID · Ovid Therapeutics Inc.

Effective: 2024-07-11
Filed: August 2, 2024, 7:59 PM ET

On June 27, 2024, Ovid Therapeutics Inc. (the “Company”) announced that Thomas Perone, the Company’s former General Counsel, Chief Compliance Officer and Corporate Secretary, would be departing from the Company in those roles, effective as of July 11, 2024 (the “Separation Date”) in connection with a workforce reduction.

Departed

Jason Tardio

Chief Operating Officer

OVID · Ovid Therapeutics Inc.

Filed: June 28, 2024, 7:59 PM ET

Jason Tardio will cease serving as the Company’s Chief Operating Officer.

Departed

Thomas Perone

General Counsel, Chief Compliance Officer and Corporate Secretary

OVID · Ovid Therapeutics Inc.

Filed: June 28, 2024, 7:59 PM ET

on the Separation Date, Thomas Perone will cease serving as the Company’s General Counsel, Chief Compliance Officer and Corporate Secretary

Appointed

Dr. Kevin Fitzgerald

director

OVID · Ovid Therapeutics Inc.

Effective: 2021-10-06
Filed: October 7, 2021, 7:59 PM ET

On October 6, 2021, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”), the Board appointed Dr. Kevin Fitzgerald, Ph.D. as a director of the Company, effective immediately.

Role change

Jeremy M. Levin

President

OVID · Ovid Therapeutics Inc.

Effective: 2021-08-27
Filed: July 8, 2021, 7:59 PM ET

the Company’s Board of Directors (the “Board”) appointed Dr. Jeremy M. Levin as President of the Company, in addition to his current duties as Chairman of the Board and Chief Executive Officer of the Company, effective upon the Officer Resignation.

Appointed

Robert Michael Poole

Class I director

OVID · Ovid Therapeutics Inc.

Effective: 2021-07-09
Filed: July 8, 2021, 7:59 PM ET

the Board appointed Dr. Robert Michael Poole as a Class I director of the Company, effective July 9, 2021

Departed

Dr. Amit Rakhit

President and Chief Medical Officer

OVID · Ovid Therapeutics Inc.

Effective: 2021-08-27
Successor: Jeremy M. Levin
Filed: July 8, 2021, 7:59 PM ET

Dr. Amit Rakhit, President and Chief Medical Officer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective August 27, 2021

Earnings & guidance

2024-Q3 EPS reported -$0.24 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

16 positive 7 negative 27 neutral

source · OVID on sec.gov